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Introduction
There is debate whether recurrent wheezing in young children represents a single disease entity, "childhood asthma", or a heterogeneous group of disorders, referred to as asthma "phenotypes".
Numerous attempts have been made to distinguish phenotypes. [1] [2] [3] A commonly used classification is the distinction between episodic viral wheeze and multiple trigger wheeze. 4, 5 Episodic viral wheeze (EVW), also called exclusive viral wheeze, characterises children who wheeze only during respiratory infections. During the intervals between colds, these children are asymptomatic. EVW is frequent in infancy and preschool years, less prevalent in older children, 6 and has also been described in adults. 7 Multitrigger wheeze (MTW) more closely resembles classical asthma. 8 Children with MTW also wheeze between respiratory infections in response to a variety of factors, including allergens, exercise, laughing or crying, strong smells or certain foods or drinks. 9 MTW is more strongly associated with lung function abnormalities 8 and atopy. 10 While most children with EVW become asymptomatic, MTW tends to persist. 11, 12 This two-phenotype model has been used to guide management of preschool wheeze. 9, [13] [14] [15] [16] For instance, a taskforce of the European Respiratory Society (ERS) recommended using inhaled corticosteroids for maintenance treatment of MTW, but montelukast for EVW. 9 The distinction between EVW and MTW and its usefulness for the management of preschool wheeze has been challenged. 17, 18 Garcia Marcos and colleagues suggested that the two phenotypes merely reflect the ends of a severity spectrum with MTW representing more severe wheeze. 19 Severity of wheeze, in particular frequency of episodes, strongly predicts long-term prognosis. 12, 20, 21 It has also been questioned whether these phenotypes are sufficiently stable over time to represent clinically meaningful entities. 22, 23 In an update of their recommendations in 2014, the ERS taskforce pointed out that wheeze patterns in young children vary over time and with treatment, rendering the distinction between EVW and MTW difficult in many patients. 17 Consequently, inhaled corticosteroids remained the first-line treatment for MTW, but 5 were also recommended for patients with frequent or severe EVW. The taskforce concluded that future research should focus on disease severity in addition to phenotypes.
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The current study used longitudinal data on wheezing at ages 2, 4, and 6 years from two large population-based birth cohorts, to examine the stability of MTW and EVW over time, and the degree to which stability was explained by differences in wheeze severity.
Material and methods

Study populations
ALSPAC is a longitudinal population-based birth cohort study that recruited 14,541 pregnant women resident in Avon, UK, with expected dates of delivery between April 1991 and December 1992. There were 14,062 live born children. The study has been described in detail elsewhere. 24 Each year up to children's age of 8 years, the study mothers were sent child health questionnaires including detailed questions on respiratory symptoms. Ethical approval was obtained from the ALSPAC Ethics and Law Committee and from Local Research Ethics
Committees.
The Leicestershire 1998-b respiratory cohort (LRC) consists of a population-based random sample of 4300 children born between May 1996 and April 1997 in Leicestershire, UK. It is, described in detail elsewhere. 25 Perinatal routine data were obtained from Leicestershire Health We include all children in both cohorts whose parents responded to a questionnaire sent at age 2, 4, or 6 years (30, 57 and 81 months' questionnaires in ALSPAC).
Definition of wheeze phenotypes 6
The questions used to address wheeze or whistling in the previous 12 months (current wheeze)
were similar in both cohorts ( Table 1) . Children were assigned to the EVW phenotype if they reported current wheeze in the previous 12 months with infections as a trigger and no other triggers ( Table 1 ). Children with current wheeze in the previous 12 months reporting a trigger category other than infections were assigned to MTW. Children with current wheeze who could not be assigned either to EVW or MTW were designated non-classifiable.
Information on wheeze severity
We defined the following indicators of wheeze severity based on symptoms in the previous 12 months: frequent wheeze attacks (≥3 in ALSPAC, ≥4 in LRC), shortness of breath during wheeze attacks, sleep disturbed due to wheezing, speech limited to 1-2 words at a time between breaths due to wheeze (ALSPAC only), wheeze interfering with child's daily activities (LRC only). The questions used to assess this information and the definitions of severity indicators are provided in the supplementary Table S1 .
Statistical analysis
We carried out the following analysis steps: a) We computed the prevalence of current wheeze, EVW and MTW at ages 2, 4, and 6 years.
b) At each age, we assessed the association between wheeze phenotypes and dichotomous indicators of severity (supplementary Table S1 ) by calculating odds ratios (OR) for MTW vs.
EVW comparing severe with less severe wheeze using logistic regression.
c) For each age interval, 2-4, 4-6, and 2-6 years, we assessed whether wheeze phenotype at the first time point (baseline) predicted current wheeze at the later time point (follow-up). We used logistic regression to estimate odds ratios (OR) for current wheeze at follow-up, comparing children with EVW and MTW at baseline with those without wheeze. 7 d) For each age interval, we assessed whether children tended to have the same wheeze phenotypes at follow-up as they did at baseline. We first calculated the probability for these categories at follow-up given the category at baseline. Using multinomial logistic regression, we then estimated relative risk ratios (RRR) for EVW and MTW at follow-up respectively comparing these phenotypes with no wheeze at baseline. We adjusted regression models for symptom severity (original variables, not dichotomised) at baseline to determine whether the phenotypes at baseline predicted the phenotypes at follow-up independent of severity. In separate models we additionally adjusted for sex, ethnicity (white, other), maternal smoking during pregnancy, older siblings (yes/no), crowding (>1 person/room) and pet ownership. The
RRRs compare the risk ratio for phenotypes at follow-up (probability for having the phenotype divided by probability of having no wheeze) in children of a given phenotype at baseline (EVW, or MTW) to children with no wheeze at baseline. We also tested for the equality of RRRs between EVW and MTW at baseline. Such equality implies absence of tracking. For instance, equality of RRRs for EVW at follow-up means that, after excluding children with MTW at follow-up, those with EVW and MTW at baseline are equally likely to have EVW at follow-up.
Results
Of the 14,062 live born children recruited in ALSPAC, we included 10,970 (78%) for whom information on wheeze was available for at least one time point (age 2, 4, or 6 years).
Information on wheeze was provided for 9953, 9391 and 8393 children at the ages of 2, 4 and 6 years respectively (Table 2) . Similarly, of the 4300 children in the LRC (1998-b cohort), we included 3263 (76%) and information on wheeze was reported for 2355, 2609 and 2077 at ages 2, 4, and 6 years respectively.
The cohorts differed with respect to ethnicity and socio-economic conditions ( Table 2) . In ALSPAC, 97% of the children were white. In the LRC, 85% were white and 15% of south Asian 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 origin. Households in the LRC tended to be more crowded, and maternal smoking and pet ownership was less common than in ALSPAC. The proportions of children whose mothers smoked during pregnancy, who had older siblings or who lived in crowded homes were lower in children who participated in only 1-2 surveys compared to those who participated in all 3, and lower still in children excluded from analyses (Supplementary Table S2 ). Maternal smoking during pregnancy was more common among children with MTW than EVW (Supplementary Table S3 ).
Prevalence of current wheeze and wheeze phenotypes at ages 2, 4 and 6 years
Prevalence of current wheeze in ALSPAC was 23% at age 2 years, and decreased to 13% at age 6 years ( Table 2) . In LRC, current wheeze decreased similarly from 23% at age 2 to 16% at age 6 years. The relative frequency of the two phenotypes were remarkably similar in both cohorts.
At age 2, 45% of all classifiable wheezers in ALSPAC (44% in the LRC) were defined as EVW; this decreased to 36% (32%) at age 4 and 30% (24%) at age 6.
Associations between wheeze phenotypes and indicators of wheeze severity
Severity of wheezing illness as defined by the five indicators (frequency of attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation) was higher for MTW than for EVW ( Table 3) . The difference between phenotypes was larger in LRC than in ALSPAC. For example, at age 2, the odds ratio (OR) for having MTW rather than EVW comparing children with frequent episodes of wheeze to those with less frequent episodes was 2.7 (95% CI: 2.2, 3.2) in ALSPAC and 6.5 (4.1, 10.4) in LRC. In the LRC, differences between the two phenotypes became more distinct (larger odds ratios) with age. years) were lower compared to the 2-year prediction intervals ( Table S6 ).
Risk of later wheeze in children with episodic viral wheeze and multiple trigger wheeze
Likelihood of keeping or switching wheeze phenotype
The proportion of children remaining in their phenotype or transitioning to another phenotype was similar in the two cohorts (Supplementary Table S5 and Figure 1 ). Among ALSPAC children who had EVW at 2 years and who had a classifiable wheezing pattern 2 years later, 57% became asymptomatic, while 21% still had EVW and 22% had developed MTW. Among children with MTW at age 2, 45% became asymptomatic, 45% remained MTW and only 10%
were reclassified to EVW.
Despite considerable proportions of children remitting or changing phenotype, multinomial logistic regressions showed a tendency of phenotypes to track: relative risk ratios (RRR) were consistently higher for remaining in the same phenotype than for phenotype switching ( Table 4 and supplementary Tables S5 and S7 ). Among children with EVW at age 2 years in ALSPAC, the crude RRR was 9.4 (95% CI: 7.4, 11.9) for EVW (stable phenotype) but 7. EVW and MTW at baseline are all <0.01 except in LRC for EVW at follow-up ( Table 4) . These p-values remain low after adjusting for symptom severity.
Discussion
Using prospectively collected data from two independent population-based cohorts, our study found that children with MTW and EVW whose wheeze persisted over two year periods (from ages 2-4 and 4-6 years) showed a tendency to remain in the same phenotype. This tracking was stronger for MTW than for EVW and was only partially explained by reported symptom severity. This supports the hypothesis that EVW and MTW represent distinct disease entities rather than different ends of a severity spectrum. Our study also confirms that a high proportion of early wheeze remits (approximately 60-70% of EVW and 40-45% of MTW). Despite differences in study design and methodology, results from the two cohorts were closely similar.
Strengths and weaknesses of the study
Our study was based on two large, population-based cohort studies that assessed wheezing prospectively. This provided large representative samples and enabled us to use phenotype definitions that are consistent over time. Both cohorts have information on frequency and severity of wheeze, which allowed us to assess whether differences in severity explained the tendency for phenotypes to track. Although the two cohorts use different measures of severity, the relationships between these markers and phenotypes are similar in both cohorts.
Phenotype definitions were based entirely on parent reports of symptoms during the previous 12 months. Parental assessment may be unreliable not only for the presence of wheeze, but also for wheeze severity and the presence of viral infections. In both cohorts, we defined phenotypes indirectly based on individual triggers of wheeze reported. Non-viral triggers may have been underreported because not all possible triggers were specifically addressed. However, in LRC, parents' direct assessment of children's wheezing pattern shows good agreement with our phenotype definitions and does not suggest under reporting of non-viral triggers (supplementary Table S8 ). EVW may have been underreported in ALSPAC, as wheeze with colds was not an explicit response option ( Table 1) . This may explain the larger proportion of non-classifiable wheeze in ALSPAC. Although both cohorts were large and population-based, not all children participated in each survey. The samples with information available at baseline and follow-up were thus somewhat reduced and not fully representative of the entire cohorts.
How do the results compare to other studies?
Our study is the largest study investigating the temporal stability of MTW and EVW and the only one to statistically test whether these phenotypes track. Furthermore, it is the only study to investigate whether this tracking is explained by symptom severity, a known risk factor for the persistence of wheeze. To our knowledge, only four studies have assessed the stability of EVW and MTW over time. 22, 23, 26, 27 Study populations were smaller than either of our two cohorts.
The results of these studies are summarised in the supplementary Table S9 . Despite differences in study population and design, the proportions of children becoming asymptomatic or changing phenotype were broadly comparable to those in our study. Two of the four studies investigated 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 both EVW and MTW and one showed, in agreement with ours, that the proportion of children remaining in the same phenotype was larger for MTV than for EVW, 22 while the other study showed greater stability for EVW. 23 However, none of these studies used regression modelling to investigate the tendency of phenotypes to track or the extent to which such a tendency might be explained by symptom severity.
Our observation that the proportion of children with MTW increases with age while EVW decreases with age is in line with other studies. 3, 6, 11, 28, 29 An early cross-sectional study showed a positive correlation of age with allergy and exercise as triggers of asthma and a negative correlation with respiratory infections. 28 Using partly overlapping data from the LRC, we have previously shown a decrease in the proportion of infections as an exclusive trigger among children with current wheeze from 57% at age 1 to 21% at age 9 years, while the proportion of children also reporting other triggers increased correspondingly. 29 Similarly, our findings that MTW is associated with more severe wheeze than EVW confirms findings from other studies. 6, 30 . Cross-sectional surveys in Aberdeen reported less frequent episodes, and less night cough, shortness of breath and chest tightness in children with EVW compared to those with MTW.
6, 30
Interpretation
In both cohorts, we found that, RRRs for EVW at follow-up were higher for children with EVW than for those with MTW at baseline, while RRRs for MTW at follow-up were higher for children with MTW at baseline. In the absence of any phenotype stability, we would have expected these RRRs to be equal. Instead, we found that children tend to remain in the same phenotype. We then explored if this was explained by differences in severity. If children with MTW on average had more severe disease, children classified as MTW at baseline would tend to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 be reclassified as MTW at follow-up. This did in fact explain part of the difference, however the direction of our findings (higher RRRs for the same phenotype) remained the same after adjusting for severity. It is possible that results are still residually confounded by unmeasured severity. Although we corrected for a wide range of measures including frequency of episodes, shortness of breath, sleep and activity disturbance, these measures were based on parental report and may be inaccurate. We also cannot exclude that the observed stability of phenotypes was partially due to parent's tendency to give the same, possibly inaccurate, answers to the same questions on symptoms over time.
It should be noted that the stability of MTW observed in our study is not an artefact of its definition: It might for instance be objected that a child by definition becomes (and remains) a multiple trigger wheezer from the first time they wheeze in response to a non-viral trigger.
However in our study, children were assigned to phenotypes based only on triggers of wheeze in the previous 12 months. Thus children wheezing only with colds during this period were classified as EVW regardless of whether they previously had MTW. This 12-month period of observation makes sense because interval symptoms may be seasonal and a classification based on shorter periods might be strongly affected by season.
Also, our study shows that EVW in preschool children should not be equated with early transient wheeze. Indeed, after adjustment, EVW had a similar predictive value for later wheeze as MTW, particularly in the ALSPAC cohort (Supplementary Table S4 )
We suspect that the explanation of our finding is that differences in the underlying diseases processes other than severity cause some children to wheeze only during respiratory tract infections and other to be sensitive to other triggers. This reopens the possibility that certain therapies might indeed be more effective in certain phenotypes. 9, 14, 16, 17 More research is needed to understand the underlying differences between EVW and MTW. Epidemiological studies should continue to distinguish between these phenotypes and better characterise them 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 regarding risk factors and prognosis. While translating such knowledge to clinical management will take time, our study suggests that we should not prematurely discard these phenotypes.
Conclusions
Using data from two large population based birth cohorts, we found that MTW and, to a lesser extent, EVW show a tendency to track from preschool to early-school age. While many children in both phenotypes become asymptomatic, those that continue to wheeze tend to remain in the same phenotype, though some phenotype switching does occur. The tendency to remain in the same phenotype was only partially explained by wheeze severity suggesting that there are other differences in the underlying disease processes of children with MTW and EVW. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Table 1 As an example for interpreting the RRR assume that among non-wheezers at baseline the risks for EVW and no wheeze at follow-up are 4% and 90% respectively. The risk ratio (RR) for EVW among non-wheezers is thus 0.044. If, in children with EVW at baseline the corresponding risks are 20% and 60%, i.e. RR=0.333, this would translate to a relative risk ratio (RRR) for EVW at follow-up of 7.5 (0.333/0.044). The regression analysis also included children with non-classifiable wheeze in a separate category (see Table 1 ) but results for this category are not reported. † Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 48 ‡ P-values of tests for equality of RRRs between EVW and MTW at baseline. Such equality implies absence of tracking. For instance, equality of RRRs for EVW at follow-up means that, after excluding children with MTW at follow-up, those with EVW and MTW at baseline are equally likely to have EVW at follow-up. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Table S1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 Table S5 Table 1 ) or no wheeze at baseline and follow-up † Results from multinomial regression analysis including non-classifiable wheeze (see Table 1 ) but results for this category are not reported here. ‡ Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 Table S7 Table 1 ) or no wheeze at baseline and follow-up † Results from multinomial regression analysis including non-classifiable wheeze (see Table 1 ) but results for this category are not reported here. ‡ Adjusted symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation). * Based on parents' response to the following questions: "Which of these two descriptions fits best your child's wheeze? 1) My child has only short attacks of wheeze, for example with colds. In between these attacks, he/she does not normally wheeze. 2) My child wheezes always or a lot of the time. With colds he/she has attacks with more severe wheeze". Episodic and chronic wheeze are defined as responses 1 and 2 respectively. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Table S9 * Numbers and percentage (parenthesis) of children with no wheeze, EVW, and MTW at follow-up among children with the given baseline phenotype (100%). † Numbers and percentage (parenthesis) of children with EVW, and MTW at follow-up among children with the given baseline phenotype who continued to wheeze at follow-up (non-wheezers at follow-up excluded). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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